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Abstract 39 
In this work, we report the preparation of a nanoparticle-based dry powder for pulmonary 40 
administration. Hybrid chitosan/hyaluronic acid nanoparticles were produced by ionotropic gelation 41 
and characterized for their physicochemical properties, being further studied by solid nuclear 42 
magnetic resonance (NMR). Using mannitol as carrier, nanoparticles were microencapsulated by 43 
spray drying, resulting in a dry powder with appropriate aerodynamic properties for lung delivery. 44 
In order to investigate the nanoparticles distribution within the carrier matrix, several techniques 45 
were applied that permitted an in-depth analysis of the system structure and surface, such as 46 
confocal laser scanning microscopy (CLSM) and X-ray photoelectron spectroscopy (XPS) in 47 
combination with time-of-flight secondary ion mass spectroscopy (TOF-SIMS). Overall, the studies 48 
conducted revealed that nanoparticles are homogeneously distributed through mannitol 49 
microspheres, suggesting the success of the microencapsulation process. In the light of these 50 
findings, it was concluded that the developed delivery system holds great potential for lung delivery 51 
of macromolecules. 52 
 53 
Key-words: Chitosan; Hyaluronic acid; Microspheres; Nanoparticles; Pulmonary administration; 54 
Spray drying; TOF-SIMS; XPS. 55 
 56 
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1. Introduction 57 
     Presently, there is particular research interest in pulmonary delivery of drugs, specially peptides, 58 
proteins and genes, not only for local, but also for systemic effect. This is primarily due to the 59 
important advantages offered by the pulmonary route, such as the large alveolar surface available 60 
for absorption, very thin diffusion path to the blood stream, extensive vascularisation, relatively low 61 
metabolic activity compared to other routes and avoidance of gastrointestinal degradation and 62 
hepatic metabolism (Agu, Ugwoke, Armand, Kinget, & Verbeke, 2001; Courrier, Butz, & 63 
Vandamme, 2002).  64 
     In spite of this, in order to succeed in the pulmonary delivery of any therapeutic molecules, 65 
many obstacles and lung defense mechanisms, that could hinder the path of foreign substances, 66 
must be overcome, such as the effect of the airways’ structure, mucociliary clearance and 67 
phagocytosis by alveolar macrophages (Courrier, Butz, & Vandamme, 2002; Hastings, Folkesson, 68 
& Matthay, 2004). Thus, to evade the impact of such barriers and to assure optimal drug delivery to 69 
the desired site, it is critical to develop the appropriate drug carriers. In this respect, specific 70 
characteristics are required which provide the drug delivery system with the ability to reach the 71 
alveolar region, if a systemic effect is desired, or another specific site, or if a local action is intended 72 
(Pandey, & Khuller, 2005). Considering the specific anatomy of the airways, it is traditionally 73 
believed that droplets and/or particles with an aerodynamic diameter within the range of 1-3 μm 74 
will present appreciable deposition in the alveolar region, while those with a higher aerodynamic 75 
diameter will mainly deposit in the upper regions (Chrystyn, 1997). Therefore, size and density of 76 
the delivery system are the most critical parameters in obtaining adequate therapeutic effects. 77 
However, notwithstanding the referred aerodynamic requirements, nanoparticles have also been 78 
recently proposed for the same end
  
(Dailey et al., 2003; Sung et al., 2007; Yang et al., 2008, Bailey 79 
et al., 2009) due to their ability to delay or avoid mucociliary clearance and macrophage capture 80 
(Schürch, Gehr, Im Hof, Geiser, & Green, 1990). 81 
4 
 
     The selection of suitable biocompatible materials (polymers, lipids, sugars) used for the 82 
preparation of lung carriers has been shown to be an essential consideration and, in this context, the 83 
polysaccharides chitosan and hyaluronan are particularly attractive polymers. Chitosan, a natural 84 
polysaccharide derived from chitin and is one of the most promising materials for transmucosal 85 
drug delivery, given its reported low toxicity, biodegradability and biocompatibility
 
(Hirano, Seino, 86 
Akiyama, & Nonaka, 1988; Issa, Koping-Hoggard, & Artursson, 2005; Varshosaz, 2007), as well as 87 
mucoadhesivity (Lehr, Bouwstra, Schacht, & Junginger, 1992; Agnihotri, Mallikarjuna, & 88 
Aminabhavi, 2004) and enhancement of macromolecules permeation (Bernkop-Schnürch, Kast, & 89 
Guggi, 2003), thus being extensively employed in the development of micro- and nanocarriers 90 
(Grenha et al., 2008). In fact, chitosan is known to be degraded by mammalian enzymes such as -91 
amylase (Muzzarelli, 1997) and lysozyme and has been demonstrated to induce low or absent 92 
toxicity in cell lines representative of the pulmonary route (16HBE14o-, Calu-3 and A549) (Lim, 93 
Forbes, Martin, & Brown, 2001; Florea, Thanou, Junginger, & Borchard, 2005; Grenha, Grainger, 94 
Dailey, Seijo, Martin, Remuñán-López, & Forbes, 2007). Hyaluronic acid is a natural, linear and 95 
non-sulfated glycosaminoglycan (Stern et al., 2007; Bastow et al., 2008; Theocharis et al., 2008; 96 
Volpi et al., 2009),
 
which is present in human tissues and fluids, mostly in soft connective tissue. 97 
Interestingly, it can be found on the surface of alveolar epithelial cells, providing protection against 98 
tissue damage and injury in a number of respiratory diseases
 
(Jiang, Liang, & Noble, 2007) and 99 
preventing pleural thickening in tuberculosis patients (Zhuo, Guo, & Tang, 2003; Cantor, & Turin, 100 
2004). 101 
     Furthermore, it has been widely implicated in the development of drug and gene delivery 102 
systems directed to different routes of administration ( Lim et al., 2002; Coradini et al., 2004; Peer 103 
et al., 2004; Brown et al., 2005; Woo et al., 2007; Hwang et al., 2008; Gómez-Gaete et al., 2008; 104 
Sahiner et al., 2008; Xin et al., 2010).
 
This interesting profile of hyaluronic acid arises from its 105 
unique characteristics, such as endogenicity, biodegradability, mucoadhesivity (Avitabile et al., 106 
2001; Morimoto et al., 2001; Mayol et al., 2008; Sivadasa., 2008), the capacity to increase drug 107 
5 
 
circulation time in vivo (Peer et al., 2004; Jiang et al., 2008), and the ability to modify drug 108 
dissolution and absorption (Chono, Li, Conwell, & Huang, 2008). Interestingly, hyaluronic acid 109 
selectively binds to CD44 receptors expressed on lung epithelial cells and over-expressed in cancer 110 
cells, a capacity that has prompted its use for targeting purposes (Akima et al., 1996; Taetz et al, 111 
2009). More specifically, it has been employed in drug inhalation and gene therapy, which have 112 
revealed encouraging in vitro and in vivo outcomes related to improved bioavailability and 113 
transfection (Akima et al., 1996; Taetz et al, 2009; Surendrakumarm et al., 2003; Rouse; 2007; 114 
Hwang et al., 2008). We recently proposed the preparation of chitosan/hyaluronic acid 115 
nanoparticles using a mild gelation technique (De La Fuente, Seijo, & Alonso, 2008a), which 116 
demonstrated great potential for ocular gene delivery (De La Fuente, et al., 2008a; De La Fuente, et 117 
al., 2008b; De La Fuente, et al., 2010). Furthermore, these nanoparticles have shown to have a 118 
potential application in the treatment of asthma, for heparin administration (Oyarzun-Ampuero, 119 
Brea, Loza, Torres, & Alonso, 2009). 120 
     It is well known that delivering nanoparticles to the lungs is impractical due to their reduced 121 
dimensions and, hence, low inertia (Sung, Pulliam, & Edwards, 2007; Yang, Peters, & Williams III, 122 
2008). To address these limitations, we have recently proposed the microencapsulation of chitosan 123 
nanoparticles within a micronsized mannitol inert carrier (Grenha, Seijo, & Remuñán-López, 2005) 124 
as an attempt to improve the nanoparticles stability (nanoparticles are administered in solid state 125 
and, therefore, more stable than the liquid counterpart) and aerosolization pattern, by conferring 126 
adequate aerodynamic properties for proper particle deposition and drug delivery in the lungs 127 
(Azarmi, Tao, Chen, Wang, Finlay, Löbenberg, & Roa, 2006; Sham, Zhang, Finlay, Roa, & 128 
Löbenberg, 2004; Freitas, Müller, & 1998). 129 
     For a better understanding of the relation between surface properties and biological performance, 130 
it is necessary to characterize in detail the surface of the developed carrier, which entails 131 
determining the composition, structure and distribution of all components present on the surface. It 132 
has been reported, specifically for dry powders, that having information on their surface 133 
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composition affords the possibility of controlling interparticulate interactions and, thus, enhancing 134 
powder dispersion during inhalation (Bosquillon, Rouxhet, Ahimou, Simon, Culot, Préat, & 135 
Vanbever, 2004; Bunkera, Daviesa, Chena, James, & Roberts, 2006; Chougule, Padhi, Jinturkar, & 136 
Misra, 2007). Thus, the investigation of surface chemistry of dry powders may be beneficial in the 137 
selection of optimal formulation and process parameters to maintain macromolecule integrity and 138 
aerosolization efficiency which definitively result in high in vivo outcomes. 139 
     Herein, we report the preparation of hybrid chitosan/hyaluronic acid nanoparticles and their 140 
characterization by NMR technique. These nanoparticles were microencapsulated in mannitol 141 
microspheres using the spray drying technique, rendering them adequate for pulmonary delivery. 142 
The mannitol microspheres´ structure was observed by confocal laser scanning microscopy (CLSM) 143 
in order to investigate the nanoparticles´ spatial distribution within mannitol microspheres 144 
following the microencapsulation process. Their surface was further analyzed by the application of 145 
two surface-sensitive analytical techniques, X-ray photoelectron spectroscopy (XPS) and static 146 
time-of-flight secondary ion mass spectrometry (TOF-SIMS), accurately characterizing their 147 
surface chemical composition and determining the presence of nanoparticles. 148 
 149 
2. Materials and methods 150 
2.1. Chemicals 151 
     Ultrapure chitosan in the form of hydrochloride salt (CS) (Protasan

 UP Cl 113, deacetylation 152 
degree 75-90%, viscosity < 20 mPa.s, molecular weight < 150 KDa) was purchased from FMC 153 
Biopolymers Norway; hyaluronic acid (HA) (molecular weight  166 KDa) was provided by 154 
Bioiberica Spain; ﬂuorescein sodium salt, phosphate buffered saline tablets (PBS) pH 7.4, 155 
pentasodium tripolyphosphate (TPP) and D-mannitol were supplied by Sigma-Aldrich Spain and 156 
Bodipy
®
 630/650-X was provided by Molecular Probes Netherlands. Ultrapure water MilliQ 157 
plus, Millipore Ibérica, Spain was used throughout. All other chemicals were reagent grade. 158 
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 159 
2.2. Preparation of chitosan/hyaluronic acid nanoparticles 160 
     Chitosan/hyaluronic acid nanoparticles were produced by a slight modification of the ionotropic 161 
gelation technique previously developed by our group (De La Fuente, Seijo, & Alonso, 2008a; 162 
Calvo, Remuñán-López, Vila-Jato, & Alonso, 1997a; Calvo, Remuñán-López, Vila-Jato, & Alonso, 163 
1997b). Electrostatic interactions were involved in the nanoparticles formation, where the positively 164 
charged amino groups of CS interact with both negatively charged HA and TPP. Briefly, solutions 165 
of TPP and HA in ultrapure water were prepared at concentrations of 0.4-2 mg/mL (w/v) and 2-4 166 
mg/mL (w/v), respectively, and then, equal volumes of both solutions were mixed. Thereafter, 1 mL 167 
of this mixture was added to 3 mL of CS solution whose concentration ranged from 1-1.25 mg/mL 168 
(w/v) and the reaction was maintained for 10 minutes under mild magnetic stirring, resulting in 169 
different formulations of nanoparticles as indicated in Table 1. Nanoparticles formed immediately 170 
and were subsequently isolated for further analysis by centrifugation on a 10 µL glycerol layer 171 
18,000×g, 30 min, 15C, Beckmann Avanti 30, Beckmann, USA, afterwards being re-suspended 172 
in 100 µL of purified water after discarding the supernatants.  173 
     For confocal laser scanning microscopy (CLSM) study, CS was labeled with fluorescein 174 
following the method described by De Campos et al (De Campos, Diebold, Carbalho, Sánchez, & 175 
Alonso, 2004). Nanoparticles were also prepared on a large scale, where the final volume of 176 
nanoparticles suspension was scaled to 40 mL. In this case, centrifugation was performed for 40 177 
min at 18,000 × g and 15 C. 178 
 179 
2.3. Determination of nanoparticles production yield 180 
     The nanoparticles production yield was calculated by gravimetry. Fixed volumes of 181 
nanoparticles suspensions were centrifuged (18,000×g, 45 min, 15 C), supernatants were discarded 182 
and sediments of nanoparticles were freeze-dried over 48 h (24 hours set at -34 C and gradual 183 
ascent until 20 C), using a Labconco Freeze Dryer Labconco, USA (n=6). 184 
8 
 
     The process yield was calculated as follows:  185 
               Nanoparticles weight 186 
Process yield (%) = ------------------------------------------------ x 100 187 
                      Total solids (CS + HA + TPP) weight 188 
 189 
2.4. Physicochemical characterization of nanoparticles  190 
     The morphological appearance of nanoparticles was examined by transmission electron 191 
microscopy (TEM) CM 12 Philips, Eindhoven, Netherlands. The samples were previously stained 192 
with 2% phosphotungstic acid and placed on copper grids with Formvar

 films for viewing. 193 
     Measurements of nanoparticles size and zeta potential were performed on freshly prepared 194 
samples, by photon correlation spectroscopy and laser Doppler anemometry, respectively, using a 195 
Zetasizer

 Nano-ZS Malvern instruments, Malvern, UK. For particle size analysis, each sample of 196 
isolated nanoparticles was diluted to the appropriate concentration with ultrapure water. Each 197 
analysis was performed at 25C at a detection angle of 173C. For the determination of zeta 198 
potential of the electrophoretic mobility, isolated nanoparticles samples were diluted with 0.1 mM 199 
KCl and placed in an electrophoretic cell, where a potential of ± 150 mV was established. Size and 200 
zeta potential of each formulation were analyzed in triplicate (n=3). 201 
 202 
2.5. Solid NMR spectroscopy of nanoparticles 203 
     Solid-state 13C CP-MAS NMR spectroscopy experiments were performed at 298 K in an 11.7 T 204 
Varian Inova-750 spectrometer (operating at 750 MHz proton frequency) equipped with a T3 205 
Varian solid probe Varian, Inc, USA. Solid NMR samples were prepared in 3.2 mm rotors with an 206 
effective sample capacity of 22 µL which corresponds to approximately 30 mg of the powder 207 
sample. The spectra were processed and analyzed with MestreNova software (Mestrelab Research 208 
Inc.). Carbon chemical shifts were assigned to the carbon methylene signal of solid adamantane at 209 
28.92 ppm.  210 
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     Four samples were analyzed: pure chitosan (CS), pure hyaluronic acid (HA), a physical mixture 211 
of equal weights of CS and HA (Mix.) and chitosan/hyaluronic acid freeze-dried nanoparticles 212 
(NPs) (CS/HA/TPP = 3.75/1/1). For each sample, a 1D-CPMAS 
13
C (cross polarization magic angle 213 
spinning) spectrum was acquired under semi-quantitative experimental conditions. The inter-scan 214 
delay was set to 3 s, the number of scans was 8000 and the MAS rate was 15 kHz. Heteronuclear 215 
decoupling during acquisition of the FID was performed with Spinal-64 with the proton field 216 
strength of 70 kHz. The cross polarization time was set to 3 ms. During cross polarization, the field 217 
strength of the proton pulse was set constant to 75 kHz and that of the 
13
C pulse was linearly 218 
ramped with a 20 kHz ramp near the matching sideband Prior to the acquisition of the 1D-CPMAS 219 
spectra of the samples, the adamantane sample was used to calibrate the maximum 
1
H-
13
C cross-220 
polarization under the experimental conditions.  221 
 222 
2.6. Preparation of dry powders containing chitosan/hyaluronic acid nanoparticles 223 
     Sediments of chitosan/hyaluronic acid nanoparticles (CS/HA/TPP = 3.75/1/1), obtained 224 
following centrifugation of the fresh nanoparticles suspensions, were resuspended in a mannitol 225 
aqueous solution and the resultant suspension of nanoparticles in mannitol was spray dried. 226 
Mannitol solutions were prepared with such concentrations that allowed final 227 
mannitol/nanoparticles to be obtained at ratios of 90/10, 80/20, 70/30 (w/w) and suspensions with a 228 
solid content of 3%. Dry powders were obtained in a one step process by spray drying either 229 
aqueous solutions of mannitol or suspensions of nanoparticles in mannitol using a laboratory scale 230 
drier Büchi Mini Spray Dryer, B-290, Switzerland. The spray drying operating conditions were: 231 
two fluids external mixing 0.7 mm nozzle, feed rate of 2.5 mL/min and inlet temperature of 170 ± 2 232 
C, resulting in outlet temperature of 111 ± 2 C. The air flow rate and the aspirator rate were 233 
constant at 400 NI/h and 70%, respectively. The resultant spray dried powders were collected and 234 
stored in a dessicator at room temperature until use. Preparation of microspheres for CLSM study 235 
was performed with mannitol labeled with the fluorophore Bodipy
 
630/650-X, which was then 236 
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mixed with the fluorescently-labeled nanoparticles (described in section 2.2) and, then co-spray 237 
dried. The labeling of mannitol with Bodipy

 was obtained by adding a solution of the fluorophore 238 
in dimethyl sulfoxide to a mannitol solution (0.32 μg Bodipy/mg mannitol), which was then kept 239 
under magnetic stirring for 1 hour. 240 
 241 
2.7. Determination of spray drying process yield 242 
     Process yield of spray drying process was determined by gravimetry establishing a comparison 243 
between the weight of resultant dry powder (microspheres) and that of the solids involved in the 244 
formulation, as follows (n=3): 245 
         Microspheres weight 246 
Process Yield (%) = ---------------------------------------------------- x 100 247 
                   Total solids (NPs + Mannitol) weight 248 
 249 
 250 
2.8. Microspheres morphological and aerodynamic characterizations 251 
     Morphology of microspheres was viewed using a scanning electron microscope (SEM, Leo, 252 
435VP, UK). Dry powders were placed onto metal plates and a 200 nm thick gold palladium film 253 
was sputter-coated on to the samples High resolution Sputter Coater SC7640, Termo VG 254 
Scientific, UK before viewing.  255 
     Aerodynamic diameter measurement was obtained using a TSI Aerosizer

 LD, equipped with an 256 
Aerodisperser

 Amherst process Instrument, Inc, Amherst, Ma, USA, whose measuring principle 257 
is based on the measurement of particles time of flight in an air stream, according to the following 258 
equation (n=3): 259 
  πd2           (Va-Vp)                              dVp 260 
Cd    ρa     =   1/6 πd
3ρp   261 
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  4                  2                                     dt 262 
where Cd: drag coefficient, d: particle diameter, ρa: density of air, Va: velocity of air, Vp: velocity of 263 
particle, and ρp: density of particle. 264 
     Real density was measured using a Helium Pycnometer Micropycnometer, Quanta Chrome, 265 
Model MPY, 2, USA. Measurements were performed in triplicate (n = 3). 266 
 267 
2.9. Structural characterization of nanoparticle-loaded microspheres using CLSM 268 
     Confocal laser scanning microscopy (CLSM) study was conducted to characterize the internal 269 
structure of nanoparticles-loaded microspheres (CS/HA/TPP = 3.75/1/1, NPs/Mannitol = 30/70 270 
(w/w)), using a TCS-SP2 vertical microscope Leica GmbH, Germany, which collects images 271 
using different fluorescent detectors and using, in this case, two laser lines: argon at 488 nm and 272 
helium-neon at 633 nm. Small samples of the dry powder composed of nanoparticles-loaded 273 
microspheres (fluorescein-labeled nanoparticles and Bodipy
®
-labeled mannitol) were placed on a 274 
glass slide and a drop of immersion oil was added to avoid particle displacement during viewing. 275 
Laser excitation wavelengths of 488 and 633 nm were used to scan the powder, and fluorescent 276 
emissions from fluorecein (emission λ = 492-550 nm) and Bodipy® (emission λ = 650-725 nm) 277 
were collected using separate channels. Images were acquired with a magnification of 63x, using an 278 
oil immersion lens (HCX PL APO Ibd. BL 63x/1.40). The gray scale images obtained from each 279 
scan were pseudo-colored green (fluorescein) and red (Bodipy
®
), and overlapped afterward (LCS 280 
Lite, Leica Confocal Software, Leica GmbH, Germany) to obtain a multicoloured image. 281 
 282 
2.10. Microspheres surface analysis using XPS and TOF-SIMS  283 
     The surface of microencapsulated nanoparticles (CS/HA/TPP = 3.75/1/1, NPs/Mannitol =30/70 284 
(w/w)), mannitol microspheres and chitosan/hyaluronic acid nanoparticles (CS/HA/TPP = 3.75/1/1) 285 
was analyzed by X-ray photoelectron spectroscopy (XPS) and time-of-flight secondary ion mass 286 
spectrometry (TOF-SIMS). To do so, powder samples (microencapsulated nanoparticles and 287 
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mannitol microspheres) or a small drop of nanoparticles suspension were directly placed on a clean 288 
polished monocrystalline silicon wafer, used as the sample holder. In the latter case, the droplet of 289 
chitosan/hyaluronic acid nanoparticles was allowed to dry at room temperature. Mannitol 290 
microspheres and chitosan/hyaluronic acid nanoparticles were used separately as controls.  291 
     XPS analysis of the samples was performed using a Thermo Scientific K-Alpha ESCA 292 
instrument VG Escalab 250 iXL ESCA, VG Scientific, U. K, equipped with aluminum Ka1, 2 293 
monochromatized radiation at 1486.6 eV X-ray source. Due to the non conductor nature of samples, 294 
it was necessary to use an electron flood gun to minimize surface charging. Neutralization of the 295 
surface charge was performed using both a low energy flood gun (electrons in the range 0 to 14 eV) 296 
and a low energy Argon ions gun. The XPS measurements were carried out using monochromatic 297 
Al-K radiation (λν=1486.6 eV). Photoelectrons were collected from a takeoff angle of 90о relative 298 
to the sample surface. The measurement was carried out in a Constant Analyzer Energy mode 299 
(CAE) with a 100 eV pass energy for survey spectra and 20eV pass energy for high resolution 300 
spectra. Charge referencing was achieved by setting the lower binding energy C1s photopeak at 301 
285.0 eV C1s hydrocarbon peak. Surface elemental composition was determined using the standard 302 
scofield photoemission cross sections. 303 
     The static time-of-flight secondary ion mass spectrometry (TOF-SIMS) analysis was performed 304 
where the mass spectra of the samples were recorded on a TOF-SIMS instrument (TOF-SIMS IV, 305 
Ion-Tof GmbH Germany). Samples were bombarded with a pulsed Bismuth ion beam. The 306 
secondary ions generated were extracted with a 10 KV voltage and their time of flight from the 307 
sample to the detector was measured in a reflectron mass spectrometer. Typical analysis conditions 308 
for this work were: 25 keV pulsed Bi3
+
 beam at 45
о
 incidence, rastered over 500 x 500 um
2
. 309 
Electron flood gun charge compensation was necessary during measurements. 310 
 311 
3. Results and discussion 312 
3.1. Preparation and characterization of chitosan/hyaluronic acid nanoparticle 313 
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     As described in the methodology section, chitosan/hyaluronic acid nanoparticles were prepared 314 
by the ionotropic gelation of the positively charged CS, mediated by the interaction with oppositely 315 
charged HA and TPP. As evidenced by TEM microphotographs displayed in Figure 1, nanoparticles 316 
showed a spherical morphology. Table 1 depicts the physicochemical properties of the resultant 317 
nanoparticles, which exhibited a positive zeta potential (+19 - +37 mV) and small sizes in the range 318 
of 173-297 nm. The formulation CS/HA/TPP = 3.75/1/1 (w/w) was selected to conduct all 319 
subsequent experiments as it displayed the highest production yield.  320 
     NMR is a well established technique for structural and dynamic characterization of molecules 321 
and for the study of organic reactions and processes either in solution, semi-solid or solid states. 322 
The NMR study of relatively high-molecular weight polymers, containing a number of carbon 323 
atoms, usually benefits from the use of solid NMR techniques (Mi, Sung, & Shyu, 2000). In this 324 
regard, the 1D-CPMAS 
13
C
 
spectra of these polymers may reveal detailed information relative to 325 
their composition with semi-quantitative results (Metz, Ziliox, & Smith, 1996). ID solid-state NMR 326 
experiments were employed here to verify the cross-linking reaction between CS and HA (Figure 2) 327 
that contributes to nanoparticles formation. More specifically, the technique can be sensitive enough 328 
to subtle changes in the electronic environments of the carbon atoms of CS and HA when they are 329 
ionically cross-linked to generate the nanoparticles. To perform this study, four samples were 330 
analyzed: nanoparticles (CS/HA/TPP = 3.75/1/1 (w/w)), pure CS and HA polymers and the physical 331 
mixture of CS and HA (Mix). The corresponding 1D-CPMAS 
13
C
 
spectra are displayed in Figure 3, 332 
each of which contains three broad signals that overlap in the band between 43-110 ppm, which is 333 
the typical region of the sugar ring carbons from C1 to C6. The signals in this band can be assigned 334 
as follows: i) region 95-110 ppm corresponds to the C1 anomeric carbons of the polymer, ii) region 335 
70-95 ppm corresponds to the carbons C2 to C5 of the polymer and iii) region 43-70 ppm 336 
corresponds to the C6 methylene carbons of the polymer. The four spectra also show the 337 
characteristic peak at ca. 174 ppm corresponding to the carboxylate and/or carbonyl acetamide 338 
carbons, as well as the carbon peak at ca. 24 ppm corresponding to the methyl group of the 339 
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acetamide group. According to these observations, all spectra elucidate the essential pattern of 340 
signals related to polysaccharide structure, but are different in the relative intensities, as depicted in 341 
Table 2. Interestingly, the integration of the signals, in Table 2, is consistent with the structures of 342 
these polymers. 343 
     According to Figure 3, there is a remarkable difference between the spectrum of nanoparticles 344 
and the other spectra, as signals in the first are considerably broader and extend over a larger region 345 
than the corresponding signals in the other spectra. Moreover, some new signals appear in the 346 
spectrum of nanoparticles, which are indicated with asterisk. The new carbon signals, resonating at 347 
ca. 135 and 205 ppm, correspond to spinning sidebands from the CO carbonyl group at ca. 175 348 
ppm. Their presence is indicative of enhanced chemical shift anisotropy of the CO group. There is 349 
also an additional signal at ca. 19 ppm that is presumably due to a methyl group of acetamide. 350 
These changes occurring to the acetamide group of CS could possibly result from re-organization 351 
due to ionic interactions between the randomly cross-linked rings of CS and HA, with effects utterly 352 
leading to a higher heterogeneity and broadening of signals in the NMR spectrum. Similar 353 
observations were described by others for solid NMR spectra of gel based systems (Saiò, Tuzi, & 354 
Naito, 1998). We can conclude, thereby, that the aforementioned changes detected in the 1D-355 
CPMAS 
13
C
 
spectra could confirm the hypothesis of the mechanism of nanoparticles formation, 356 
which involves cross-linking via electrostatic and hydrophobic interactions between the CS and HA 357 
in addition to that contributed by the TPP cross-linker through the gelation process. 358 
 359 
3.2. Microspheres preparation and characterization 360 
     Nanoparticles were co-spray dried with mannitol in a one-step spray–drying process with yields 361 
around 65-70 %. As stated in the introduction, the microencapsulation step envisages the 362 
improvement of nanoparticles aerosolization pattern and lung deposition, which are mainly driven 363 
by the aerodynamic parameters of inhaled particles (e.g. size, density) (Vanbever, Mintzes, Wang,  364 
Nice, Chen, Batychy,  Langer, & Edwards, 1999; Larhrib, Martin, Prime, & Marriott, 2003; Minne,  365 
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Boireau, Horta, & Vanbever, 2008). The resultant microencapsulated nanoparticles were viewed by 366 
SEM (Figure 4), evidencing spherical morphology and demonstrating less tendency to aggregate as 367 
the nanoparticles load increased with respect to mannitol. Microspheres exhibited a real density of 368 
1.45 g/cm
3 
and an aerodynamic diameter of 2.6 µm (Table 3), which are suitable characteristics to 369 
achieve deep lung deposition (Bosquillion, Lombry, Préat, & Vanbever, 2001; Mustante, Schroeter, 370 
Rosati, Crowder, Hickey, & Martonen, 2002). 371 
     The application of sensitive techniques to characterize the structure of dry powders provides 372 
important information that helps to elucidate the behavior of these drug delivery systems in 373 
subsequent studies, both in vitro and in vivo. CLSM has been used to this end, since it allows us to 374 
acquire high resolution optical sections of x-y scans along the z-axis, which are then reconstructed 375 
into 3-D multicolored views, enabling a complete visualization of the dry powder external and 376 
internal structure, as well as the spatial arrangement of the components (Lamprecht, Schäfer, & 377 
Lehr, 2000). In our work, the acquisition of fluorescent images by CLSM enabled us to precisely 378 
detect the nanoparticles location within the microspheres. This could not be attained by SEM, which 379 
only provides information on the particles surface structure, rather than its internal structure. Figure 380 
5(a-c) displays the images of microsphere encapsulating chitosan/hyaluronic acid nanoparticles. An 381 
outer shell composed of mannitol (red channel) and an even distribution of chitosan/hyaluronic acid 382 
nanoparticles throughout the microsphere matrix can be observed. The presence of a mannitol outer 383 
shell is confirmed by Figure 5(d), which further evidences microspheres spherical shape as 384 
previously observed by SEM. The homogeneous nanoparticles distribution within the mannitol 385 
microspheres without detecting any punctuate green signals of aggregated particles in the 386 
microspheres matrix may lead to the assumption that mannitol is almost entirely located at the 387 
particles’ surface. This was also verified by the optical cross-sections of the confocal images (not 388 
shown) which suggest that the microsphere matrix is almost occupied by the fluorescent 389 
nanoparticles. It has been shown that sugar stabilizers, like mannitol, tend to preferentially adsorb at 390 
the air/liquid interface during the drying process (Arakawa, & Timasheff, 19982; Wang, Chua, & 391 
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Wang, 2004). Therefore, we may hypothesize that non-specific interactions occurred between the 392 
mannitol and the hydrophobic fluorophore (Bodiby

), displacing the positively charged 393 
nanoparticles inwards. It is noteworthy that these findings are similar to those reported in previous 394 
studies for microparticles designed for inhalation therapy (Ely, & Finlay, 2007).
 
395 
     XPS and TOF-SIMS represent a complementary approach as non destructive and surface-396 
sensitive analytic techniques. However, the particular interest of their application in the study of 397 
drug delivery systems arises from the capability of these techniques to provide quantitative and 398 
qualitative information of surface composition (De Vries, E, 1998), which provides valuable 399 
information for the interpretation of kinetic and dynamic behavior, such as drug dissolution, 400 
stability, distribution and release (Chesko, Kazzaz, Ugozzoli, Singh, O’hagan, Madden, Perkins, & 401 
Patel, 2008; Dahlberg, Millqvist-Fureby, & Schuleit, 2008). Additionally, using these tools, the 402 
encapsulation efficiency of microencapsulated drugs
 
(Xie, Marijnissen,  & Wang, 2006; Morales, 403 
Ruiz, Oliva, Oliva, & Gallardo, 2007) or nanoparticles
 
(Grenha, Seijo, Serra, & Remuñán- López, 404 
2007).can also be assessed. This latter approach was our goal in the present study. Considering the 405 
fact that microspheres have a lot of surface contact due to their powdery nature, the adsorption of 406 
atmospheric natural contaminants such as nitrogen (N), is highly probable, therefore sample 407 
surfaces were sputter cleaned using a soft argon ion beam (Ar+/1KV, /60 sec, 2X1 mm2). The 408 
signals of the contaminating N in the powder samples almost disappeared (preliminary data not 409 
shown), indicating that it was weakly bound (adsorbed) and, thus, easily removed.  410 
     As displayed in Table 4, however very weak N signals were detected in these samples (values 411 
below 0.1 AT%), which could be explained on the basis that the ionic barrel is 45 degrees to the 412 
surface, generating areas of shadow where the argon ions cannot reach. By contrast, the N signal in 413 
the chitosan/hyaluronic acid nanoparticles spectrum persisted after the sputter cycle with a 414 
relatively high value, suggesting that it is chemically bonded and which could be ascribed to CS. 415 
Moreover and as expected, both Na and P, ascribed to TPP in the nanoparticles, were detected 416 
solely on the surface of chitosan/hyaluronic acid nanoparticles; whereas were absent on the surface 417 
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of either mannitol microspheres or microencapsulated nanoparticles. Taking into account the 418 
detection limit of XPS (all elements except H: ~ 0.01 monolayer, or ~ 0.1% bulk), this finding 419 
indicates the absence of TPP on the powder surfaces. Our assumption of efficient nanoparticles 420 
microencapsulation can be further reinforced by the C/O ratio, which is similar for mannitol 421 
microspheres and the microencapsulated nanoparticles (1.15 and 1.12, respectively). Interestingly, 422 
this ratio is different from that of chitosan/hyaluronic acid nanoparticles (1.6), suggesting that the 423 
surfaces of both mannitol microspheres and the microencapsulated nanoparticles are similar in 424 
terms of the atomic composition and concentrations of C and O. Additionally, the higher C/O ratio 425 
for the chitosan/hyaluronic acid nanoparticles implies lower surface concentration of O, which is 426 
due to the contribution of other elements detected on the surface. It is worth while to notice here 427 
that a signal for silicon was identified in some spectra which could be originated from the silicon 428 
wafer used as a sample support during the analysis (Grenha, Seijo, Serra, & Remuñán- López, 429 
2007). 430 
     This result was also confirmed by deconvolution analysis of the spectra where the high 431 
resolution spectra of carbon (C1s) signals, showing an envelope, were curve fitted using the 432 
Gaussian distribution into a series of peaks corresponding to different functional groups. We have 433 
assigned as reference the peak at the lowest binding energy (285.0 eV) to carbon atoms linked to 434 
carbon and hydrogen atoms. Table 5 summarizes the relative peak area of each carbon environment. 435 
As can be seen, the peak areas (%) and relative intensities of (C-C, 285 eV), (C-O, 286.8 eV) and 436 
(C=O, 288.37 eV) are nearly similar in mannitol microspheres and microencapsulated 437 
nanoparticles. More importantly, the peak of (O-C=O, 289.54 eV), unique for CS, was detected in 438 
the spectrum of chitosan/hyaluronic acid nanoparticles but not in the other two samples. The 439 
analysis of this result was also confirmed by deconvolution analysis of the spectra where the high 440 
resolution spectra of carbon (C1s) signals, showing an envelope, were curve fitted using the 441 
Gaussian distribution into a series of peaks corresponding to different functional groups. We have 442 
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assigned as reference the peak at the lowest binding energy (285.0 eV) to carbon atoms linked to 443 
carbon and hydrogen atoms. 444 
     Table 5 summarizes the relative peak area of each carbon environment. As can be seen, the peak 445 
areas (%) and relative intensities of (C-C, 285 eV), (C-O, 286.8 eV) and (C=O, 288.37 eV) are 446 
nearly similar in mannitol microspheres and microencapsulated nanoparticles. More importantly, 447 
the peak of (O-C=O, 289.54 eV), unique for CS, was detected in the spectrum of 448 
chitosan/hyaluronic acid nanoparticles but not in the other two samples. The analysis of 449 
deconvoluted C1s high resolution spectra re-affirms that chitosan/hyaluronic acid nanoparticles are 450 
entirely encapsulated in mannitol microspheres. 451 
     TOF-SIMS analysis was conducted under non-destructive energetic conditions and under the 452 
static limit (10 
12
 ions/cm
3
). In the mass spectra, positive ions were detected. According to the 453 
spectra displayed in Figure 6, the nanoparticles spetrum differs from those of both microsphere 454 
samples in the existence of some molecular fragments [m/z = 232(C16H24O), 205(C15H9O), 455 
200(C10H16O4)] in addition to the main and most representative ions of mannitol observed at m/z = 456 
183 (the molecular ion + H) and the two times molecular ion + H observed at m/z = 365. At the 457 
same time, many identified molecular fragments of nanoparticles, not observed in the spectra of 458 
microspheres and located at m/z = 189(C7H13O4Si), 202(C12H10O3), 215(C11H12O3Na), 459 
239(C15H11O3) and 226(C18H10), could result basically from the fragmentation of both CS and HA. 460 
Furthermore, other intensive signals for fragments containing N and O are clearly observed in the 461 
nanoparticles but not in mannitol microspheres and microencapsulated nanoparticles, located at m/z 462 
= 60(C2H6NO), 59(C2H5NO), 58(C2H4NO) and which could arise from the fragmentation of CS 463 
(Figure 7-1). The N-containing fragment (C2H4NO, m/z = 58), identified as intensive in the 464 
nanoparticles sample, was detected however in both microsphere samples but in one order of 465 
magnitude lower, which is likely due to the atmospheric exposure as mentioned previously (Figure 466 
7-2). Importantly, the PO3 fragment (m/z =79), attributed to TPP, is intensive and clearly observed 467 
in the nanoparticles sample whereas it is not detected in that of mannitol microspheres and its 468 
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intensity in microencapsulated nanoparticles is at least one order of magnitude lower than that of 469 
nanoparticles sample (Figure 8). 470 
     According to our observations from these spectra, the samples of mannitol microspheres and the 471 
microencapsulated nanoparticles, if not identical, are very similar (intensity of the identified 472 
fragments and also the distribution of the intensity between ions). These outcomes demonstrate that 473 
chitosan/hyaluronic acid are efficiently encapsulated within the mannitol carrier, especially if we 474 
refer to the fact that the TOF-SIMS technique is qualified with the highest surface sensitivity for 475 
surface analysis (detection limit range of ppm-ppb, orders of magnitude better than XPS) and the 476 
resolution depth of 1-3 monolayers.  477 
 478 
4. Conclusion 479 
     Chitosan/hyaluronic acid nanoparticles were prepared, characterized and microencapsulated in 480 
mannitol microspheres, resulting in a dry powder that shows adequate aerodynamic properties for 481 
deep pulmonary deposition. Following the encapsulation process, structural analysis of the dry 482 
powder was provided by CLSM, which elucidated that the nanoparticles were homogeneously 483 
distributed within the mannitol microsphere. The evidence that nanoparticles were completely 484 
encapsulated within the carrier by means of the spray drying process, was achieved by application 485 
of the sensitive surface analysis techniques, XPS and TOF-SIMS. These outcomes confirm the 486 
success of nanoparticles microencapsulation by spray drying. We expect, thereby, that the 487 
microencapsulated nanoparticles hold promise for pulmonary delivery of macromolecules such as 488 
proteins and nucleic acids, as these nanoparticles have demonstrated great potential in gene 489 
transfection in ocular cell lines (De La Fuente, Seijo, & Alonso, 2008b). Therefore, further work is 490 
required to investigate the delivery potential of these developed carriers, in the form of dry powders 491 
in pulmonary cell lines. 492 
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Table 1. Process yields and physiochemical properties of chitosan/hyaluronic acid nanoparticles 
(CS/HA NPs), prepared with different concentrations of hyaluronic acid (HA), tripolyphosphate 
(TPP) and chitosan (CS) (mean ± S.D., n = 3). 
 
CS/HA/TPP 
(w/w/w) 
Yield 
(%) 
Size 
(nm) 
Z potential 
(mV) 
3.75/1/1 
4.3/1.1/1 
4.3/1.4/1 
5.0/1.3/1 
5.0/1.7/1 
5.0/2.5/1 
6.3/3.1/1 
7.5/3.8/1 
9.4/4.7/1 
15.0/10/1 
56 ± 8 
44 ± 1 
45 ± 2 
41± 4 
48 ± 2 
56 ± 1 
40 ± 4 
41 ± 3 
33 ± 1 
23 ± 9 
233 ± 3 
239 ± 4 
275 ± 20 
297 ± 23 
212 ± 4 
254 ± 6 
241 ± 5 
219 ± 7 
197 ± 4 
173 ± 1 
+ 37 ± 2 
+ 35 ± 1 
+ 34 ± 1 
+ 34 ± 1 
+ 25 ± 1 
+ 23 ± 1 
+ 20 ± 1 
+ 26 ± 1 
+ 25 ± 1 
+ 19 ± 1 
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Table 2. Chemical shifts (ppm) and signal integrations obtained from the 
13
C 1D- CPMAS spectra 
of the samples studied: pure chitosan (CS), pure hyaluronic acid (HA), physical mixture of both 
polymers (Mix), and chitosan/hyaluronic acid nanoparticles (NPs) (CS/HA/TPP =3.75/1/1). The 
relative area of the 
13
C NMR signal is indicated between parentheses. 
 
 
 
Chemical Shift (ppm)  
Simple 
C1 to C6 
(sugar)
a
 
CO 
(acetamide)
b
 
CO 
(glucuronic)
b
 
CH3 
(acetamide)
c
 
CO* 
d 
CS 
43-110 
(27.3) 
174.2 
(1.0) 
 
--- 
22.8 
(0.8) 
 
--- 
HA 
43-110 
(7.26) 
173.6 
(1.0) 
22.6 
(0.39) 
 
--- 
Mix 
43-110 
(7.75) 
173.9 
(1.0) 
22.6 
(0.67) 
 
--- 
NPs 
43-110 
(7.75) 
174.2 
(1.0) 
22.6 
(0.98) 
214.0 
(0.31) 
     a: Integral from 43 to 110 ppm, b: Integral from 163 to 185 ppm, c: Integral from 12  to 34 ppm, d: Integral 
          from 205 to 222 
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Table 3. Aerodynamic properties of dry powders prepared with different mannitol/ nanoparticles 
weight ratios and solids contents (CS/HA/TPP = 3.75/1/1, mean ± S.D., n = 3). 
 
Mannitol/ 
nanoparticles 
ratio 
Solids content
a
 
(%) 
Feret’s diameterb       
(µm) 
Real density 
(g/cm
3
) 
Aerodynamic 
diameter (µm) 
70/30 3.0 2.3 ± 0.7 1.45 ±0.06 2.57 ± 0.08 
80/20 2.8 2.7 ± 1.3 1.45 ±0.12 ND 
90/10 3.0 2.2 ± 0.4 1.45 ±0.17 ND 
a: Solids content represents the total solids concentration (%) of the spraying suspensions, b: Feret’s diameters are 
    determined by optical microscopy 
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Table 4. Surface elemental composition (atomic %), determined by XPS, of chitosan/hyaluronic 
acid nanoparticles (CS/HA NPs), mannitol microspheres (M) and microencapsulated nanoparticles 
(M-NPs) (CS/HA/TPP = 3.75/1/1, mannitol/ nanoparticles = 70/30). 
 
Element (%) CS/HA NPs M M-NPs 
C 53.2 52.5 43.0 
O 33.5 45.6 38.5 
N 5.2 0.10 0.10 
Na 1.4 0 0 
P 4.6 0 0 
Si 
S 
1.4 
0.7 
0 
1.7 
12.5 
5.9 
ratio C/O 1.6 1.15 1.12 
C: carbon, O: oxygen, N: nitrogen,  Na: sodium, P: phosphorus. Si: silicon, S: sulpher. 
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Table 5. The relative peak area (%) of each carbon environment for chitosan/hyaluronic acid 
nanoparticles (CS/HA NPs), mannitol microspheres (M) and microencapsulated nanoparticles (M-
NPs) (CS/HA/TPP = 3.75/1/1, mannitol/nanoparticles = 70/30). 
 
Sample C-C/C-H 
285eV 
C-O  
286.8eV 
C=O 
288.4eV 
O-C=O 
289.5eV 
CS/HA NPs 36.0 45.7 14.2 4.1 
M 29.3 61.6 9.1 0 
M-NPs 39.0 56.1 4.9 0 
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Figure legends: 
 
Figure 1. TEM microphotographs of chitosan/hyaluronic acid nanoparticles (CS/HA/TPP = 
3.75/1/1). 
 
Figure 2. A numbering scheme for hyaluronic acid (above) and chitosan (bottom) polysaccharides 
where GlcA, GlcNAc, and Glc refer to glucuronic acid, N-acetyl glucose amine and glucose amine, 
respectively. 
 
Figure 3. Solid-state 13C-NMR spectra of chitosan/hyaluronic acid nanoparticles (NPs) 
(CS/HA/TPP = 3.75/1/1), chitosan (CS), hyaluronic acid (HA), and the physical mixture of CS with 
HA (Mix) (CS/HA = 3.75/1). The signal assignment is indicated. In the spectrum of NPs, some 
signals that are not present in the other samples are labeled with an asterisk and discussed in the 
text. 
 
Figure 4. SEM microphotographs of microencapsulated chitosan/hyaluronic acid nanoparticles 
(CS/HA/TPP = 3.75/1/1) at different mannitol/nanoparticles theoretical ratios (w/w): (a) 90/10, (b) 
80/20, (c) 70/30. 
 
Figure 5. Confocal microscopy images of a mannitol microsphere loaded with chitosan/ hyaluronic 
acid nanoparticles (CS/HA/TPP = 3.75/1/1, mannitol/nanoparticles = 30/70 (w/w): (a) a green 
channel representing the fluorescently-labeled nanoparticles, (b) a red channel representing 
mannitol labeled with Bodipy
®
, (c) channels overlapping; and (d) a section of mannitol 
microspheres containing the nanoparticles with both overlapping channels. The scale bars in panels 
(a-c) amounts to 4 microns and that in panel (d) amounts to 10 microns. 
 
Revised legends of Figures
2 
 
Figure 6. Mass spectra obtained by TOF-SIMS, showing the region of molecular ion + H
+ 
of 
mannitol for (a) mannitol microspheres, (b) microencapsulated nanoparticles (CS/HA/TPP = 
3.75/1/1, mannitol/ nanoparticles = 70/30 (w/w) and (c) chitosan / hyaluronic acid nanoparticles 
(CS/HA/TPP = 3.75/1/1). 
 
Figure 7. Mass spectra obtained by TOF-SIMS, showing (Fig. 10-1): N and O containing fragments 
in (a) mannitol microspheres, (b) microencapsulated nanoparticles (CS/HA/TPP = 3.75/1/1, 
NPs/Mannitol = 30/70 (w/w)), (c) chitosan/hyaluronic acid nanoparticles (CS/HA/TPP = 3.75/1/1); 
and (Fig. 10-2): the fragment C2H4NO at m/z = 58 in the same samples. 
 
Figure 8. Mass spectra obtained by TOF-SIMS, showing the region of phosphate fragments for the 
samples: (a) mannitol microspheres, (b) microencapsulated nanoparticles (CS/HA/TPP = 3.75/1/1, 
mannitol/nanoparticles = 70/30 (w/w), (c) chitosan/hyaluronic acid nanoparticles (CS/HA/TPP = 
3.75/1/1). 
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